The Process Optimization of Pichia pastoris GS115LI for Producing Fused Protein of LL-37 and IFN-α2a

Abstract

Abstract: With experiments of single factor, the optimal process of recombinant P. pastoris GS115LI for producing fused protein of LL-37 and IFN-α2a were using BMMY as inducing medium, inoculum as OD₆₀₀=5.5, temperature as 26℃, pH6.0, inducing chemical（methanol）adding amount as 1.0% every 24 h, incubating shaking speed as 200 r/min, and inducing time as 144 h. Under those optimal conditions, the 27.9 mm of LL-37 antimicrobial activity could be gotten. Compared with the original conditions, the productivity of fused protein of LL-37 and IFN-α2a was increased as 32.29%.

Key words: Interferon-α2a , LL-37 , Fermentation process

Zhang Mingjie. The Process Optimization of Pichia pastoris GS115LI for Producing Fused Protein of LL-37 and IFN-α2a[J]. Biotechnology Bulletin, 2014, 0(11): 214-218.

References

[1]Borden EC, Sen GC, Uze G, et al. Interferons at age 50：past, current and future impact on biomedicine[J]. Nature Reviews Drug Discovery, 2007, 6（12）：975-990.
[2]Pestka S. The interferons：50 years after their discovery, there is much more to learn[J]. Journal of Biological Chemistry, 2007, 282（28）：20047-20051.
[3]O' Brien TR. Interferon-alfa, interferon-lambda and hepatitis C[J]. Nat Genet, 2009, 41（10）：1048-1050.
[4] Beilharz MW, Cummins JM, Bennett AL. Protection from lethal influenza virus challenge by oral type 1 interferon[J]. Biochemical and Biophysical Research Communications, 2007, 355（3）：740-744.
[5] Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis：a retrospective monocentric study of 45 patients[J]. British Journal of Ophthalmology, 2007, 91（3）：335-339.
[6] Chen X, Niyonsaba F, Ushio H, et al. Synergistic effect of antibacterial agents human β-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli[J]. Journal of Dermatological Science, 2005, 40（2）：123-132.
[7] Mookherjee N, Lippert DND, Hamill P, et al. Intracellular receptor for human host defense peptide LL-37 in monocytes[J]. The Journal of Immunology, 2009, 183（4）：2688-2696.
[8] Kai-Larsen Y, Agerberth B. The role of the multifunctional peptide LL-37 in host defense[J]. Frontiers in Bioscience：A Journal and Virtual Library, 2007, 13：3760-3767.
[9] Jacobsen F, Mittler D, Hirsch T, et al. Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections[J]. Gene Therapy, 2005, 12（20）：1494-1502.
[10] 柯野, 罗晓春, 谢明权.米曲碱性蛋白酶基因的克隆表达及水解特性研究[J].华南理工大学学报：自然科学版, 2012, 40（8）：40-45.
[11]汤鸣强, 薛盛果, 叶鹏.米曲霉F-81产中性蛋白酶的固定化条件及其特性[J].生物技术通报, 2012（3）：159-165.
[12]杨云霞, 朱玲, 王伯瑶, 等.人抗菌肽LL-37突变分子的特性和抗菌能力的比较.华西药学杂志, 2006, 21（5）：422-424.
[13]Dannehl C, Gutsmann T, Brezesinski G. Surface activity and structures of two fragments of the human antimicrobial LL-37[J]. Colloids and Surfaces B：Biointerfaces, 2013, 109：129-135.
[14]Shen J, Lu X, Jin X, et al. Expression of a novel dual-functional protein-The antimicrobial peptide LL-37 fused with human acidic fibroblast growth factor in Escherichia coli[J]. Protein Expression and Purification, 2012, 81（1）：119-125.
[15]Charoenrat T, Khumruaengsri N, Promdonkoy P, et al. Improvement of recombinant endoglucanase produced in Pichia pastoris KM71 through the use of synthetic medium for inoculum and pH control of proteolysis[J]. Journal of Bioscience and Bioengineering, 2013, 116（2）：193-198.
[16] Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37：an antimicrobial peptide with a role in inflammatory skin disease[J]. Annals of Dermatology, 2012, 24（2）：126-135.
[17]Potvin G, Ahmad A, Zhang Z. Bioprocess engineering aspects of heterologous protein production in Pichia pastoris：A review[J]. Biochemical Engineering Journal, 2012, 64：91-105.
[18]Lo TM, Teo WS, Ling H, et al. Microbial engineering strategies to improve cell viability for biochemical production[J]. Biotechnology Advances, 2013, 31（6）：903-914.